IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Why AtaiBeckley Stock Soared Today The psychedelic drugmaker is being acquired.
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
This GLP-1 Stock Could Double by 2030. Here's Why Investors need to ask tough questions before initiating a position in this biotech company.
Why Is GH Research Stock Trading Higher on Thursday? GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.
Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’ Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED) AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today Eli Lilly (
NYSE:LLY ) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.
Why Vivosim Labs Shares Are Rocketing on Wednesday? VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.
3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.
